[MEDICAL IP Accelerates Market Leadership in Al Health Screening with Nationwide Supply]
MEDICAL IP announced that it has signed a supply agreement with the Korea Association of Health Promotion(KAHP) for its X-ray-based Al health screening solution, DeepCatch X.
This large-scale rollout marks a major milestone in MEDlCAL IP's commercialization journey, positioning thecompany as a frontrunner in the digital transformation of health screening. The nationwide implementation isexpected to significantly enhance both the company's commercial scalability and industry credibility, laying afirm foundation for market expansion across Korea.
DeepCatch X is an innovative Al solution that extracts and visualizes diverse health insights from a single chestX-ray image. The system quantitatively analyzes critical anatomical structures, such as the 3D maximumdiameter of the aorta and the size of the heart, helping users better understand their health status throughintuitive visuals.
Particularly noteworthy is DeepCatch X's ability to detect the early signs of life-threatening cardiovascularconditions-such as aortic dissection or rupture-which often develop without noticeable symptoms. Thismakes it a powerful example of digital twin technology contributing to proactive health management withincritical time windows.
KAHP is the largest health screening institution in Korea, operating 17 regional centers nationwide andconducting over 4 milion health screenings annually. According to the association, approximately 3 milionchest X-rays are performed each year for screening purposes. The adoption of DeepCatch X across KAHP'snetwork is expected to further embed Alpowered analysis as a mainstream tool in clinical settings.
"We believe MEDlCAL iP's DeepCatch solution alians perfectly with our future-oriented vision of shifting fromdisease prevention to disease prediction," said Kim In-Won, President of KAHP. "We hope the Al-generatedinsights will empower examinees to better understand their health and take proactive steps toward personalhealth management."
"This deployment represents a meaningful evolution in the clinical value of conventional medical imaging" saidSang Joon Park, CEO of MEDICAL IP. "The collaboration with Korea's largest health screening institution isDarticularly significant, and we are proud to see the DeepCatch series achieve nationwide adoption in less thana year since launch. We will continue accelerating our leadership in the Al-driven health screening market."